ACP
HRTX icon

Acuta Capital Partners’s Heron Therapeutics HRTX Stock Holding History

Acuta Capital Partners’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-101,050
Closed -$1.02M – 59
2014
Q4 		$1.02M Buy
+101,050
New +$825K 0.69% 44

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acuta Capital Partners's HRTX Position: Q1 2015 in Review

Acuta Capital Partners sold out of Heron Therapeutics (HRTX) in Q1 2015, closing a stake of 101,050 shares — an estimated $1.02M sold.

Acuta Capital Partners first reported a position in HRTX in Q4 2014 and held it in 1 quarter. The position peaked at $1.02M in Q4 2014. 69 funds tracked by Wall St. Rank hold HRTX as of Q1 2015.

  • Acuta Capital Partners reported no remaining Heron Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Acuta Capital Partners sold 101,050 Heron Therapeutics shares in Q1 2015, an estimated $1.02M.
  • Acuta Capital Partners first reported a position in Heron Therapeutics in Q4 2014 and held it in 1 quarter.
  • Acuta Capital Partners's Heron Therapeutics position peaked at $1.02M in Q4 2014.
  • 69 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2015.

Based on Acuta Capital Partners's 13F filing for Q1 2015, filed 15 May 2015.